ANSTO Publications Online >
Journal Publications >
Journal Articles >

Please use this identifier to cite or link to this item: http://apo.ansto.gov.au/dspace/handle/10238/8986

Title: In vivo PET imaging with [18F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes
Authors: Cochran, BJ
Ryder, WJ
Parmar, A
Tang, S
Reilhac, A
Arthur, A
Charil, A
Hamze, H
Barter, PJ
Kritharides, L
Meikle, SR
Gregoire, MC
Rye, K
Keywords: Diabetes mellitus
Fluorodeoxyglucose
Insulin
Kinetics
Positron computed tomography
Simulation
Lipoproteins
Radiopharmaceuticals
Phosphorylation
Issue Date: 18-May-2016
Publisher: Springer Nature
Citation: Cochran, B. J., Ryder, W. J., Parmar, A., Tang, S., Reilhac, A., Arthur, A., Charil, A., Hamze, H., Barter, P. J., Kritharides, L. Meikle, S. R., Gregoire, M. C., & Meikle, S. R. (2016). In vivo PET imaging with [18F] FDG to explain improved glucose uptake in an apolipoprotein AI treated mouse model of diabetes. Diabetologia, 59(9), 1977-1984. http://doi.org/10.1007/s00125-016-3993-5
Abstract: Type 2 diabetes is characterised by decreased HDL levels, as well as the level of apolipoprotein A-I (apoA-I), the main apolipoprotein of HDLs. Pharmacological elevation of HDL and apoA-I levels is associated with improved glycaemic control in patients with type 2 diabetes. This is partly due to improved glucose uptake in skeletal muscle.© 2016 Springer Nature
URI: https://link.springer.com/article/10.1007%2Fs00125-016-3993-5
http://apo.ansto.gov.au/dspace/handle/10238/8986
ISSN: 1432-0428
Appears in Collections:Journal Articles

Files in This Item:

There are no files associated with this item.

Items in APO are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback